Matthew Galsky
Matthew Galsky
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | Muscle Invasive Bladder Urothelial Carcinoma | Recruiting | Phase 2 | 2026-08-05 | NCT06809140 | |
| Pembrolizumab in Muscle-invasive Bladder Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urothelial carcinoma | Active, not recruiting | Phase 2 | 2026-04-08 | NCT05406713 |